泛昔洛韦治疗HBV慢性感染的临床研究

目的：观察泛昔洛韦对HBV慢性感染抗病毒的治疗效果。方法：慢性乙型肝炎患者89例，采用随机对照分组，和单用泛昔洛韦治疗组32例，和单用α－干扰素29例和单用拉米夫定28例两个对照组，对比观察三组抗病毒治疗效果。结果：治疗组泛昔洛韦血清HBV DNA阴转率40．62％（13／32），HBeAg阴转率21．88％（7／32）；对照组α－干扰素血清HBV DNA阴转率37．93％（11／29），HBeAg阴转率41．38％（12／29）；拉米夫定血清HBV DNA阴转率67．90％（19／28），HBeAg阴转率21．43％（6／28）。治疗组HBV DNA阴转时间最短1个月，最长3个月，平均1．3个月，无1例出现严重不良反应。结论：泛昔洛韦治疗HBV慢性感染安全有效。

Famciclovir treatment of patients with chronic hepatitis B virus infection

Objective To evaluate the effects of famciclovir treatment of patients with chronic hepatitis B virus (HBV) infection.Methods Eighty nine patients with chronic HBV infection were randomly divided into three groups. Thirty two patients were treated with famciclovir, 29 patients and 28 patients with chronic HBV infection were treated with interferon (IFN) alpha and lamivudine, respectively, as the control. Results The serum HBV DNA became negative after treatment in 40.62% (13/32) of patients treated with famciclovir, 37 93% (11/29) of patients treated with IFN alpha, and 67.90% (19/28) of patients treated with lamivudine. The rate of serum HBeAg loss for the three groups were 21.88% (7/32), 41.38% (12/29) and 21.43% (6/28) , respectively. The average time for patients to become serum HBV DNA negative was 1.3 months. Conclusion Famciclovir is an effective and safe nucleoside drug for the treatment of patients with chronic HBV infection.